Related Experiment Video

Updated: May 23, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Thrombosis in myeloproliferative and myelodysplastic syndromes

Raffaele Landolfi1, Leonardo Di Gennaro

  • 1Catholic University School of Medicine, Institute of Internal Medicine and Geriatrics, Haemostasis Research Center, Largo Agostino Gemelli 8, 00168 Rome, Italy. rlandolfi@rm.unicatt.it

Hematology (Amsterdam, Netherlands)
|April 18, 2012
PubMed

Insights

Myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) increase thrombosis risk. This review covers thrombophilia aspects in MPNs and MDS, crucial for understanding patient morbidity and mortality.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) are clonal stem cell disorders.
  • Arterial and venous thromboses are primary causes of morbidity and mortality in polycythemia vera and essential thrombocythemia (types of MPNs).
  • Thromboses and hemorrhages complicate MDS natural history, often due to platelet abnormalities and treatment side effects.

Purpose of the Study:

  • To review the main aspects of thrombophilia in myelodysplastic syndromes and myeloproliferative neoplasms.

Main Methods:

  • Literature review focusing on thrombophilia in MPNs and MDS.

Main Results:

  • Thrombosis is a major complication in MPNs and MDS.
  • Platelet quantitative and qualitative anomalies contribute to thrombotic and hemorrhagic risks in MDS.
  • Understanding thrombophilia is key to managing these myeloid disorders.

Conclusions:

  • Thrombophilia is a significant clinical concern in MPNs and MDS.
  • Further research into thrombophilia mechanisms and management is warranted for these myeloid stem cell disorders.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...